TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BBIO stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight BridgeBio Pharma’s potential for significant growth. The company’s recent performance with Attruby prescriptions exceeded expectations by 32%, suggesting robust market demand and potential revenue growth that could reach up to $200 million by 2025. This optimistic outlook is further supported by the pipeline of promising Phase III programs, which are expected to yield data in the near future.
Additionally, Attruby’s favorable label, pricing strategy, and its unique approach to treatment are key differentiators in the market. The drug’s ability to achieve near-complete TTR stabilization and its impact on reducing cardiovascular-related hospitalizations and deaths make it attractive to physicians. Despite potential competition from upcoming drugs, BridgeBio’s strategic positioning and recent successes underpin Van Buren’s positive outlook and Buy recommendation.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $95.00 price target.